MetaCap

ArriVent BioPharma (AVBP) vs Bicara Therapeutics (BCAX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

ArriVent BioPharma (AVBP) has outperformed Bicara Therapeutics (BCAX) over the past year, losing 48.3% versus a loss of 53.2%. Bicara Therapeutics is the larger company by market cap ($560.3 million vs $544.1 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AVBP-48.30%BCAX-53.22%
+77%+7%-62%
Nov 21, 20251 yearNov 20, 2026
AVBP-55.72%BCAX-63.95%
+51%-9%-69%
Sep 9, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AVBP versus BCAX key metrics
MetricAVBPBCAX
Share price$10.52$8.44
Market cap$544.13M$560.31M
1-day change-6.57%-7.46%
YTD return-47.71%-49.85%
1-year return-48.30%-53.22%
EPS (TTM)$-3.60$-3.46
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-166.31M$-137.95M
52-week high$35.83$30.99
52-week low$10.33$7.87
Distance from 52-week high-70.64%-72.77%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+149.05%+281.16%
Average volume1.37M1.20M
Shares outstanding51.72M66.39M
Employees77103
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About ArriVent BioPharma

AVBP stock →

ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients.

Health Care · Biotechnology: Pharmaceutical Preparations · 77 employees

About Bicara Therapeutics

BCAX stock →

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors.

Health Care · Biotechnology: Pharmaceutical Preparations · 103 employees

AVBP vs BCAX FAQ

Which is bigger, ArriVent BioPharma or Bicara Therapeutics?

Bicara Therapeutics (BCAX) is larger, with a market capitalization of $560.31M compared with $544.13M for ArriVent BioPharma (AVBP).

Which stock has performed better over the past year, AVBP or BCAX?

AVBP returned -48.30% over the past 12 months, compared with -53.22% for BCAX (price return, excluding dividends). Past performance does not predict future results.

Are ArriVent BioPharma and Bicara Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons